Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan Enjoys Uptick As It Prepares For Pfizer Merger

Executive Summary

With Mylan on track to achieve more than $1bn in new product sales in 2019, recent US launches of the firm’s Wixela Inhub rival to Advair Diskus and Fulphila pegfilgrastim biosimilar helped to propel it to growth in the second quarter, despite still reporting an overall decline in the first half of the year.

You may also be interested in...



Pfizer Deal Will Dramatically Reshape Mylan’s Model

Following the announcement of a merger between Mylan and Pfizer’s Upjohn, the top executive team that will take charge of the combination has set out its vision for the company.

Pfizer To Merge Off-Patent Business With Mylan

Pfizer has announced plans to merge its off-patent unit with Mylan, creating a new generics and biosimilars giant in the US.

Mylan gets warning for Morgantown site

Mylan has suffered a further manufacturing setback at its flagship facility in Morgantown, US, after the US Food and Drug Administration (FDA) issued the site with a warning letter concerning its finished-dosage forms. Following an inspection at the plant from 19 March to 12 April, the agency identified “significant violations” of current good manufacturing practice (cGMP) and said it may withhold new approvals linked with the site.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB140560

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel